{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 25 of 128', 'Change in systemic antihistamine therapy within 2 weeks prior to', 'baseline i.e., subjects must not start antihistamine treatment or change', 'the current dosage regime within 2 weeks prior to baseline.', 'Other cutaneously applied therapy on the hands (except for the use of', \"subject's own emollients) within 1 week prior to baseline.\", 'Cutaneously applied treatments in regions other than the hands, which', 'could interfere with clinical trial evaluations or pose a safety concern', 'within 1 week prior to baseline.', 'Treatment with any marketed biological therapy or investigational', 'biologic agents (including immunoglobulin, anti-IgE, and dupilumab):', 'Any cell-depleting agents including but not limited to', 'rituximab: within 6 months prior to baseline, or until', 'lymphocyte count returns to normal, whichever is longer.', 'Other biologics: within 3 months or 5 half-lives, whichever is', 'longer, prior to baseline.', 'Clinically significant infection within 4 weeks prior to baseline which,', 'in the opinion of the investigator, may compromise the safety of the', 'subject in the trial, interfere with evaluation of the IMP, or reduce the', \"subject's ability to participate in the trial. Clinically significant\", 'infections are defined as:', 'A systemic infection.', 'A serious skin infection requiring parenteral (intravenous or', 'intramuscular) antibiotics, antiviral, or antifungal medication.', 'Tuberculosis requiring treatment within 12 months prior to screening', 'and/or subjects with a positive blood test for tuberculosis at screening*', '* Subjects with high risk of latent tuberculosis (e.g. prior residence in', 'or travel to countries with high prevalence of tuberculosis, close', 'contact with a person with active tuberculosis, or a history of active or', 'latent tuberculosis where an adequate course of treatment cannot be', 'confirmed) must be tested.', 'History of any known primary immunodeficiency disorder including a', 'positive human immunodeficiency virus (HIV) test at screening, or the', 'subject taking antiretroviral medications as determined by medical', \"history and/or subject's verbal report.\", 'Positive hepatitis B surface antigen (HBsAg), hepatitis B surface', 'antibody (HBsAb), hepatitis B core antibody (HBcAb), or hepatitis C', 'virus antibody (anti-HCV) serology at screening. Subjects with positive', 'HBsAb may be randomised provided they are hepatitis B vaccinated', 'and have negative HBsAg and HBcAb.', 'Any disorder, including but not limited to cardiovascular,', 'gastrointestinal, hepatic, renal, neurological, musculoskeletal,', 'infections, endocrine, metabolic, haematological, immunological,', 'psychiatric, or major physical impairment, which is not stable in the', 'opinion of the investigator and could:', 'Affect the safety of the subject throughout the trial.', 'Influence the findings of the trial or their interpretations.', \"Impede the subject's ability to complete the entire duration of\", 'the trial.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 26 of 128', 'Investigational', 'Name of IMP: delgocitinib cream', 'medicinal product', 'Active substance: delgocitinib', '(IMP)', 'Formulation: cream', 'Formulation strength: 1, 3, 8, and 20 mg/g and vehicle', 'Dose and method of administration: twice daily topical application', 'Duration of', '16 weeks.', 'treatment', 'Number of', 'A total of 250 eligible subjects will be randomised in a 1:1:1:1:1 ratio to', 'subjects', 'delgocitinib cream 1, 3, 8, or 20 mg/g or delgocitinib cream vehicle.', 'A lower limit of 20% and an upper limit of 30% will be imposed on the IGA', 'baseline severity of subjects with mild and severe chronic hand eczema,', 'respectively. Based on this capping, the overall number of subjects in each', 'severity group can range between:', 'Mild: 50 to 75 subjects.', 'Moderate: 100 to 150 subjects.', 'Severe: 50 to 75 subjects.', 'Number and', 'Approximately 25 sites in Europe and North America.', 'distribution of', 'trial sites', 'Statistical', 'A dose-response modelling approach will be applied for the primary endpoint', 'methods', 'IGA TS at Week 16 and the secondary endpoint change in HECSI from', 'baseline to Week 16. The dose-response relationship will be modelled by', '3 identified candidate models selected based on the expected dose-response', 'relationship for delgocitinib cream.', 'In addition, for binary endpoints the difference in response rates between', 'treatment groups will be analysed using the Cochran-Mantel-Haenszel test and', 'continuous endpoints will be analysed using a repeated measurements model.', 'For the primary and secondary endpoints, the selection of the dose-response', 'model that fits data best will be controlled using a family-wise error rate of 5%.', 'There will be no adjustment for the multiple testing of primary and secondary', 'endpoints, all p-values will be considered nominal.', 'Signatory', 'PDD', ', MD, PhD, Department of Clinical Social Medicine,', 'investigator', 'Occupational and Environmental Dermatology, University Hospital', 'Heidelberg, Germany.', 'Sponsor', 'LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark.']\n\n###\n\n", "completion": "END"}